

Index to Volume Twenty-five

Index of Issues: January, 1-56; February, 57-118; March, 119-180; April, 181-224; May, 225-272; July, 273-330; August, 331-394; September, 395-450; October, 451-500; November, 501-578.

INDEX OF AUTHORS

- A**
 Ağaçfidan A, 448
 ACSF-investigators, 437
 Ajayi AO, 237
 Alonso JM, 366
 Ang O, 448
 Aral SO, 90, 130, 232, 378, 455
 Arquez JM, 569
 Ashley R, 82
 Augenbraun M, 1, 569
 Aydin MD, 448
- B**
 Bachmann L, 1
 Ballenger A, 539
 Banda M, 254
 Beardsley L, 509
 Beck-Sagué C, 533
 Beebe JL, 265
 Bell D, 303
 Bellin EY, 303
 Belongia EA, 169
 Beltrami JF, 501
 Bertrand JR, 169
 Bhullar V, 533
 Bianchi A, 366
 Bierman R, 509
 Biggar RJ, 237
 Black CM, 5, 49, 225, 533
 Blackwell R, 427
 Blattner WA, 237
 Blin P, 118
 Bliss MJ, 561
 Bloch J, 118
 Bloom A, 427
 Bogard M, 366
 Bohbot JM, 366
 Bolan G, 222
 Boles J, 273
 Borobio MV, 569
 Bou-Saada I, 139
 Bowden FJ, 322
 Bowser B1
 Branson B, 539
 Branson BM, 553
 Brathwaite W, 108
 Brown W, 243
 Bruce S, 361
 Buchbinder SP, 296
 Bull SS, 457
 Bullard JC, 225
 Burk RD, 509
 Burstein GR, 395
- C**
 Calcinai A, 24
 Candal DH, 225, 533
 Cannon RO, 553
 Capps L, 443
 Carolina J, 310
 Carrillo C, 82
 Carré N, 476
 Cates W Jr, 151
 Caul O, 14
 Celum C, 296
 Cessot G, 366
 Chama D, 254
- Chan LY, 464
 Chen CY, 408
 Chen Z, 533
 Chernesky M, 14
 Cheung WM, 464
 Choi ST, 211
 Chong LY, 464
 Clark AM, 421
 Clay-Warner J, 273
 Cohen DA, 501, 544
 Cohen M, 527
 Cohen SS, 368
 Cohn DL, 353
 Coles FB, 5
 Connolly A-M, 20
 Cook RL, 144
 Corby NH, 353
 Corey L, 58
 Crissman CE, 132
 Cristofani R, 24
- D**
 Dada AJ, 237
 Daling JR, 278, 285
 Daniel R, 243
 D'Souza P, 293
 Davidsson S, 44
 De Lalla F, 451
 DeHovitz J, 49
 DeMers SM, 421
 Di Fabrizio N, 451
 Diamondstone L, 237
 Dicker LW, 251, 310
 Donovan B, 505
 Douglas J, 222
 Douglas JM Jr., 457, 468
 Doyle M, 443
 Drew WL, 481
 Drociuk D, 211
 DuBouchet L, 1, 176
 Duran R, 161
 Dussaix E, 476
- E**
 Edlin BR, 154
 Ehret JM, 522
 Eitrem R, 433
 El-Sadr W, 443
 Ellen HM, 130
 Erenius M, 433
 Escamilla J, 82
 Estébanez P, 194
 Evans P, 154
 Evans T, 361
- F**
 Facer M, 100
 Farley TA, 501, 544
 Farshy CE, 49, 533
 Faruque S, 154
 Feldman J, 49
 Fenaughty AM, 38
 Finelli L, 132
 Fishbein M, 353
 Fisher DG, 38
 Fitzgerald S, 49
 Ford WL, 342
- Fortenberry JD, 76
 Fox KK, 386
 Foxman B, 90, 232
 Frerichs RR, 342
 Fresia AE, 331
 Friedman SR, 219
 Frost A, 243
 Fullilove RE, 130
- G**
 Gaydos CA, 108, 395, 406, 450
 Giacomini G, 24
 Girdner J, 450
 Giuliani M, 221
 Glanton V, 533
 Glaser JB, 308
 Glover LH, 139
 Gollub EL, 483
 Gore S, 217
 Gossack JP, 265
 Gotuzzo E, 82
 Graham D, 303
 Grant JC, 194
 Gray RH, 450
 Greenblatt RM, 137
 Greenspan JR, 49
 Gross M, 296
 Grumet S, 317
 Gunn RA, 49, 132, 218
 Güvener Z, 448
- H**
 Habel LA, 278, 285
 Halsey N, 331
 Hamers FR, 28
 Hammond KR, 427
 Hamrick JT, 501
 Handsfield HH, 12
 Haraoka M, 489
 Harper SL, 218
 Harrison A, 20
 Hatch K, 361
 Hatch S, 154
 Heagerty P, 296
 Hennessy M, 561
 Hershow RC, 527
 Hillier SL, 421
 Hillis SD, 5
 Hiltunen-Back E, 181
 Hira SK, 196
 Ho GYF, 509
 Holbrook KA, 303
 Holloway B, 408
 Holmes KK, 82, 90, 232
 Hook EW III, 1
 Hortin G, 427
 Hovell MF, 49
 Howell MR, 108, 406
- I**
 Iatesta M, 222
 Inciardi J, 154
 Irwin KL, 154
 Ismail M, 176
- J**
 Jamkhedkar PP, 196
- Joesoef R, 549
 Joffe A, 395
 Johnson D, 154
 Johnson R, 549
 Johnson RE, 225
 Johnson SR, 533
 Jones DL, 187
 Jónsdóttir K, 44
 Jose B, 219
 Joyanes P, 569
 Judson FN, 522
- K**
 Kacergis J, 331
 Kadioglu A, 448
 Kalish LA, 527
 Kamb M, 222
 Karim SSA, 20, 346
 Karlsson SM, 44
 Katamine S, 516
 Kautiainen H, 181
 Kawagoe K, 516
 Kettinger LD, 211
 Khanna N, 293
 Kilmarx PH, 28
 Knapp JS, 425
 Kobayashi I, 489
 Kotloff KL, 243
 Kurokawa K, 516
 Kusano Y, 516
- L**
 Labes K, 161
 Landesman S, 49
 Lanjewar DN, 196
 Laurent AA, 211
 Lawson ML, 427
 Lefèvre J-C, 350
 Lepri AC, 211
 Leroux T, 457
 Leung CS, 464
 Levine WC, 225, 251, 386
 Li C, 450
 Liao A, 76
 Libman M, 418
 Limnios EA, 415, 505
 Litchfield B, 5
 Liu H, 408
 Ljubicic M, 569
 Luinstra K, 14
 Lum G, 505
 Lurie M, 20
 LèPargneur J-P, 350
- M**
 Macaluso M, 427
 Macke BA, 561
 Madger LS, 130
 Maguire RA, 494
 Mahony J, 14
 Malkin JE, 366
 Malotte K, 211
 Mancuso S, 451
 Manif 2000 Study Group, 483
 Mann JM, 455
 Martin DH, 501
 Martin DL, 169

Index to Volume Twenty-five

Index of Issues: January, 1-56; February, 57-118; March, 119-180; April, 181-224; May, 225-272; July, 273-330; August, 331-394; September, 395-450; October, 451-500; November, 501-578.

INDEX OF AUTHORS

- A**
 Ağaçfidan A, 448
 ACSF-investigators, 437
 Ajayi AO, 237
 Alonso JM, 366
 Ang O, 448
 Aral SO, 90, 130, 232, 378, 455
 Arquez JM, 569
 Ashley R, 82
 Augenbraun M, 1, 569
 Aydin MD, 448
- B**
 Bachmann L, 1
 Ballenger A, 539
 Banda M, 254
 Beardsley L, 509
 Beck-Sagué C, 533
 Beebe JL, 265
 Bell D, 303
 Bellin EY, 303
 Belongia EA, 169
 Beltrami JF, 501
 Bertrand JR, 169
 Bhullar V, 533
 Bianchi A, 366
 Bierman R, 509
 Biggar RJ, 237
 Black CM, 5, 49, 225, 533
 Blackwell R, 427
 Blattner WA, 237
 Blin P, 118
 Bliss MJ, 561
 Bloch J, 118
 Bloom A, 427
 Bogard M, 366
 Bohbot JM, 366
 Bolan G, 222
 Boles J, 273
 Borobio MV, 569
 Bou-Saada I, 139
 Bowden FJ, 322
 Bowser B1
 Branson B, 539
 Branson BM, 553
 Brathwaite W, 108
 Brown W, 243
 Bruce S, 361
 Buchbinder SP, 296
 Bull SS, 457
 Bullard JC, 225
 Burk RD, 509
 Burstein GR, 395
- C**
 Calcinai A, 24
 Candal DH, 225, 533
 Cannon RO, 553
 Capps L, 443
 Carolina J, 310
 Carrillo C, 82
 Carré N, 476
 Cates W Jr, 151
 Caul O, 14
 Celum C, 296
 Cessot G, 366
 Chama D, 254
- Chan LY, 464
 Chen CY, 408
 Chen Z, 533
 Chernesky M, 14
 Cheung WM, 464
 Choi ST, 211
 Chong LY, 464
 Clark AM, 421
 Clay-Warner J, 273
 Cohen DA, 501, 544
 Cohen M, 527
 Cohen SS, 368
 Cohn DL, 353
 Coles FB, 5
 Connolly A-M, 20
 Cook RL, 144
 Corby NH, 353
 Corey L, 58
 Crissman CE, 132
 Cristofani R, 24
- D**
 Dada AJ, 237
 Daling JR, 278, 285
 Daniel R, 243
 D'Souza P, 293
 Davidsson S, 44
 De Lalla F, 451
 DeHovitz J, 49
 DeMers SM, 421
 Di Fabrizio N, 451
 Diamondstone L, 237
 Dicker LW, 251, 310
 Donovan B, 505
 Douglas J, 222
 Douglas JM Jr., 457, 468
 Doyle M, 443
 Drew WL, 481
 Drociuk D, 211
 DuBouchet L, 1, 176
 Duran R, 161
 Dussaix E, 476
- E**
 Edlin BR, 154
 Ehret JM, 522
 Eitrem R, 433
 El-Sadr W, 443
 Ellen HM, 130
 Erenius M, 433
 Escamilla J, 82
 Estébanez P, 194
 Evans P, 154
 Evans T, 361
- F**
 Facer M, 100
 Farley TA, 501, 544
 Farshy CE, 49, 533
 Faruque S, 154
 Feldman J, 49
 Fenaughty AM, 38
 Finelli L, 132
 Fishbein M, 353
 Fisher DG, 38
 Fitzgerald S, 49
 Ford WL, 342
- Fortenberry JD, 76
 Fox KK, 386
 Foxman B, 90, 232
 Frerichs RR, 342
 Fresia AE, 331
 Friedman SR, 219
 Frost A, 243
 Fullilove RE, 130
- G**
 Gaydos CA, 108, 395, 406, 450
 Giacomini G, 24
 Girdner J, 450
 Giuliani M, 221
 Glanton V, 533
 Glaser JB, 308
 Glover LH, 139
 Gollub EL, 483
 Gore S, 217
 Gossack JP, 265
 Gotuzzo E, 82
 Graham D, 303
 Grant JC, 194
 Gray RH, 450
 Greenblatt RM, 137
 Greenspan JR, 49
 Gross M, 296
 Grumet S, 317
 Gunn RA, 49, 132, 218
 Güvener Z, 448
- H**
 Habel LA, 278, 285
 Halsey N, 331
 Hamers FR, 28
 Hammond KR, 427
 Hamrick JT, 501
 Handsfield HH, 12
 Haraoka M, 489
 Harper SL, 218
 Harrison A, 20
 Hatch K, 361
 Hatch S, 154
 Heagerty P, 296
 Hennessy M, 561
 Hershow RC, 527
 Hillier SL, 421
 Hillis SD, 5
 Hiltunen-Back E, 181
 Hira SK, 196
 Ho GYF, 509
 Holbrook KA, 303
 Holloway B, 408
 Holmes KK, 82, 90, 232
 Hook EW III, 1
 Hortin G, 427
 Hovell MF, 49
 Howell MR, 108, 406
- I**
 Iatesta M, 222
 Inciardi J, 154
 Irwin KL, 154
 Ismail M, 176
- J**
 Jamkhedkar PP, 196
- Joesoef R, 549
 Joffe A, 395
 Johnson D, 154
 Johnson R, 549
 Johnson RE, 225
 Johnson SR, 533
 Jones DL, 187
 Jónsdóttir K, 44
 Jose B, 219
 Joyanes P, 569
 Judson FN, 522
- K**
 Kacergis J, 331
 Kadioglu A, 448
 Kalish LA, 527
 Kamb M, 222
 Karim SSA, 20, 346
 Karlsson SM, 44
 Katamine S, 516
 Kautiainen H, 181
 Kawagoe K, 516
 Kettinger LD, 211
 Khanna N, 293
 Kilmarx PH, 28
 Knapp JS, 425
 Kobayashi I, 489
 Kotloff KL, 243
 Kurokawa K, 516
 Kusano Y, 516
- L**
 Labes K, 161
 Landesman S, 49
 Lanjewar DN, 196
 Laurent AA, 211
 Lawson ML, 427
 Lefèvre J-C, 350
 Lepri AC, 211
 Leroux T, 457
 Leung CS, 464
 Levine WC, 225, 251, 386
 Li C, 450
 Liao A, 76
 Libman M, 418
 Limnios EA, 415, 505
 Litchfield B, 5
 Liu H, 408
 Ljubicic M, 569
 Luinstra K, 14
 Lum G, 505
 Lurie M, 20
 LèPargneur J-P, 350
- M**
 Macaluso M, 427
 Macke BA, 561
 Madger LS, 130
 Maguire RA, 494
 Mahony J, 14
 Malkin JE, 366
 Malotte K, 211
 Mancuso S, 451
 Manif 2000 Study Group, 483
 Mann JM, 455
 Martin DH, 501
 Martin DL, 169

Masloboeva HA, 468
 McCormack W, 1
 McCormack WM, 176
 McCoy HV, 154
 McFarlane MM, 561
 McGill W, 222
 McGill WL, 468
 McGregor JA, 176
 McKay TL, 421
 McKnight B, 278, 285
 McMahon DJ, 317
 McQuillan GM, 225
 Meehan M, 450
 Meeuwisse A, 433
 Mertz KJ, 225
 Messiah A, 118
 Meyer L, 437, 476
 Mikaelian L, 14
 Miller K, 222
 Miller MA, 418
 Miller WC, 201
 Mills WA, 169
 Minkoff H, 49
 Misra RS, 293
 Moatti J-P, 483
 Moji K, 516
 Mojica B, 5
 Moncada J, 14
 Moran JS, 386
 Moretti D, 24
 Moreyra L, 82
 Morrison CS, 260
 Morrison EAB, 509
 Morse SA, 408
 Mosure DJ, 251
 Mphuka S, 254
 Mulhall BP, 505
 Musaba E, 260
 Muyinda GK, 254

N

Naccash RM, 211
 Nagafuji T, 489
 Nakashima AK, 386
 Nakayama H, 489
 Neaton JD, 443
 Neu NM, 317

O

O'Donnell CR, 161
 O'Donnell L, 161
 Obadia Y, 483

Ortiz CG, 457

P

Paavonen J, 14, 181
 Pandhi RK, 293
 Patton DL, 421
 Paul I, 14
 Peng G, 443
 Perea EJ, 569
 Peterman TA, 28, 310, 539, 553
 Pettus KS, 533
 Phillips DM, 494
 Piedrahita C, 139
 Pillay A, 408
 Plourde PJ, 254
 Podschun GD, 49
 Poindexter AN III, 335
 Pope V, 549
 Potterat JJ, 154
 Pálsdóttir R, 44

Q

Quinn T, 450
 Quinn TC, 108, 237, 395, 406

R

Rabe LK, 421
 Ramjee G, 346
 Ransom R, 553
 Rattan A, 293
 Reunala T, 181
 Rey D, 483
 Rezza G, 221
 Rhodes SD, 211
 Rietmeijer CA, 353, 455
 Robain M, 476
 Roddy RE, 151
 Rolfs R, 549
 Ronald AR, 254
 Rosenberg MJ, 144
 Rosenthal SL, 368
 Rostila T, 181
 Rothenberg RB, 154
 Rotily M, 217
 Ruiz J, 100
 Russ K, 243

S

Saika T, 489
 Saiman L, 317
 Sales V, 418
 Salmon-Ceron D, 476

San Doval A, 161
 Sangi-Haghpeykar H, 335
 Schachter J, 14, 229
 Schilling R1
 Schmitt K, 5
 Schrader M, 154
 Schulz KF, 151
 Scribner RA, 544
 Seage GR III, 296
 Sellors J, 14
 SEROCO Study Group, 476
 Serwadda D, 450
 Sewankambo NK, 450
 Sha B, 527
 Shah K, 243
 Shapiro S, 243
 Sherman KJ, 278, 285
 Shlay JC, 468
 Shroff HK, 196
 Shultz TR, 415
 Shultz TR, 505
 Shuter J, 303
 Sichali-Sichinga K, 254
 Simon PA, 342
 Sinicco A, 451
 Spina M, 451
 St. Louis ME, 5, 132, 225
 Staat MA, 331
 Stamm W, 82
 Stamm WE, 12
 Stanberry LR, 368
 Steiner B, 408
 Steiner MJ, 139
 Steingrímsson Ó, 44
 Stergachis A, 278
 Stergachis A, 285
 Sterk C, 1548
 Sturm AW, 346, 408
 Sun RK, 100
 Sunkutu MR, 260
 Sweeney YTC, 421
 Swenson P, 82
 Sy FS, 211
 Syphilis and HIV Study Group, 549
 Sánchez J, 82

T

Tabara SO, 243
 Tanaka M, 489
 Tang Y-L, 331
 Tapsall JW, 415, 505

The ACSF Group, 118
 The Field Epidemiology Network for STDs (FENS), 132
 The Multicenter Crack Cocaine and HIV Infection Study Team, 187
 Till M, 527
 Tirelli U, 451
 Toomey KE, 154, 310
 Toye B, 14
 Traina C, 451
 Trizna Z, 361
 Tyring SK, 361

V

Vaccher E, 451
 Van Den Eeden SK, 278, 285

W

Wallace T, 1
 Warner L, 273
 Warszawski J, 437
 Wasserheit JN, 378
 Wasserman SS, 243
 Waterfield G, 395
 Wawer MJ, 450
 Webb KH, 403
 Weiland C, 217
 Westhoff C, 317
 Whittington WL, 386
 Wiley DJ, 342
 Wilkinson D, 20
 Williamson J, 273
 Wilson TE, 70
 Wolitski RJ, 353
 Wong EL, 260
 Word C, 154
 Wroten JE, 310

X

Xu K, 533

Y

Yamamoto T, 516
 Yu CW, 464

Z

Zacharopoulos VR, 494
 Zaidi AA, 310, 386, 553
 Zenilman J, 222, 331
 Zenilman JM, 395
 Zimet GD, 76

A

- Aboriginal Canadian women, HPV infection in, 55 (letter)
 Acid phosphatase, as semen biomarker, in condom failure, 427
 Adolescents
 African American, STD incidence in, sexual behavior and, 125, 130 (editorial)
 female
 screening of, for chlamydia and gonorrhea, 395
 STDs in, racial/ethnic differences in, 125, 130 (editorial)
 topical microbicides for, 368
 high-risk, use of general health and STD services by, 457
 high-risk male, *C. trachomatis* screening in, 49
 screening for, peer outreach for, 49
 urine ligase chain reaction testing in, for *N. gonorrhea*, 533
 Africa
 Nigeria, genital ulcer disease and HIV in sex workers in, 237
 South Africa
 sexually transmitted diseases in, health facility-based surveillance for, 20
 STD prevalence in female sex workers, 346
 African Americans
 adolescent, STD incidence in, sexual behavior and, 125, 130 (editorial)
 diversity of sexual repertoire of, high-risk behavior and, 232
 Alcohol use/abuse
 gonorrhea prevalence and, 544
 high-risk sexual behavior and, 38, 119
 underreporting of, 220, 221 (letters)
 Anal intercourse. *See also* Sexual behavior
 female STD incidence and, 90
 rectal microbicides for, 296
 unprotected, in young male homosexuals, 100
arp gene, PCR of, in subtyping of *T. pallidum*, 408
 ASTDA Achievement Award, 57
 Australia, quinolone-resistant *N. gonorrhoeae* in, 415, 425 (editorial)
 Azithromycin
 for *C. trachomatis*, vs. doxycycline, 5, 12 (editorial)
 for chlamydia, test-of-cure by PCR and transcription-mediated amplification for, 366
 for gonorrhea, treatment outcome/MIC correlates for, 505

B

- Bacterial vaginosis
 cervical/vaginal cytology for, 24
 in South African sex workers, 346
 Barrier contraceptives. *See also* Condoms
 for at-risk oral contraceptive users, 139
 Book review, *Clinician's Manual on Genital Herpes* (Cunningham et al.), 216

C

- Canadian Aboriginal women, HPV infection in, 55 (letter)
 Cancer, cervical, screening for, yield of in STD clinic, 368
 Carrageenan-based nonoxynol-9, 494
 Cefibuten, for gonorrhea, 464
 Cervical abnormalities, screening for in STD clinic, yield of, 468
 Cervical cytology, for bacterial vaginosis, 24
 Cervical human papillomavirus infection
 in Canadian Aboriginal vs. non-Aboriginal women, 55 (letter)
 detection of in college women, 243
 risk assessment scale for, 509
 Cervical infection, pelvic inflammatory disease and, social and behavioral correlates of, 378
 Chancroid, ciprofloxacin vs. erythromycin vs. cotrimoxazole for, 293
Chlamydia trachomatis
 tetracycline-resistant strain of, in vitro susceptibility of, 350
 urethral colonization with, 448 (letter)
Chlamydia trachomatis infection
 azithromycin for, test-of-cure by PCR and transcription-mediated amplification for, 366
 0.25% chlorhexidine gluconate gel for, 421
 contact tracing for, in Sweden, 433

- doxycycline for
 vs. azithromycin, 5, 12 (editorial)
 compliance with, 1, 12 (editorial)
 enzyme-linked immunoassay for, false-positive results of, 418
 Gen-Probe PACE 2 assay for
 in male arrestees, 501
 PCR confirmation of, DNA purification in, 265
 persistence/recurrence of, behavioral vs. pharmacologic factors in, 12
 PID and, social and behavioral correlates of, 378
 prevalence of
 national probability sample survey for, 225
 positivity as proxy for, 251
 in pregnancy, in Japan, 516
 prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 rapid detection of, by Cobas Amplicor vs. LCx, 44
 screening for, 227 (editorial)
 DNA amplification assays for, 108
 cost-effectiveness of, 403, 406 (letters)
 in middle school students, 395
 in high-risk adolescent males, 49
 in middle school students, 395
 money-saving benefits of, 53 (letter)
 national pilot survey for, 225
 prevalence-based program for, 201
 self-collected vaginal swabs for, 450 (letter)
 serologic diagnosis of, 14
 sex during menses and, 90
 in South African sex workers, 346
 in urban family planning clinic population, 317
 urine leukocyte esterase testing for, in males, 322
 0.25% Chlorhexidine gluconate gel, for *C. trachomatis*, 421
 Ciprofloxacin
 for chancroid, vs. erythromycin and cotrimoxazole, 293
 N. gonorrhoeae resistance to, 415, 425 (editorial), 522
 Client education, video-based, in urban STD clinic, 161
 Cobas Amplicor, vs. LCx, for rapid detection of *C. trachomatis*, 44
 Cocaine use
 high-risk sexual behavior and, 38, 119
 by men who have sex with men, 353
 by sex workers, 187
 HIV serostatus and STD incidence and, 70
 underreporting of, hepatitis C transmission and, 220, 221 (letters)
 College women, detection of genital HPV infection in, 243
 Commercial sex workers. *See* Sex workers
 Compliance, with doxycycline therapy, 1, 12 (editorial)
 Condoms
 in CMV infection prevention, 481
 effectiveness of, user practices and, 273
 failure of, objective markers of, 427
 female
 awareness and use of, 222 (letter)
 long-term use of, in Zambian high-risk populations, 260
 with rectal microbicides, 296
 use of
 by at-risk oral contraceptive users, 139
 by female sex workers
 HIV prevalence and, 451
 STD prevalence and, 82
 by French prisoners having heterosexual intercourse, 217 (letter)
 by Italian sex workers, 451
 by men who have sex with men, drug abuse and, 353
 after STD diagnosis, gender differences in, 437
 by women undergoing tubal ligation, 335
 Condylomata acuminata
 interferon for, 361
 risk factors for
 in females, 285
 in males, 278
 Contact tracing. *See also* Partner notification
 for chlamydia, in Sweden, 433
 Contraceptives, barrier. *See also* Condoms

- for at-risk oral contraceptive user, 139
- Cotrimoxazole, for chancroid, vs. erythromycin and ciprofloxacin, 293
- Counseling
 - group, for STD/HIV prevention, 553
 - for HIV-infected clients, 28
 - risk assessment-based, 539
- Crack cocaine. *See* Cocaine use
- Cytology, cervical/vaginal, for bacterial vaginosis, 24
- Cytomegalovirus infection
 - in HIV infection, incidence of and risk factors for, 476, 481 (editorial)
 - prevention of by condoms, 481 (editorial)

D

- DNA amplification assays
 - in *C. trachomatis* screening, 108
 - in chlamydia screening
 - cost-effectiveness of, 403, 406 (letters)
 - in middle school students, 395
- DNA purification, for PCR testing of Gen-Probe PACE specimens, 265
- Douching, STD incidence and, 90
- Doxycycline, for chlamydia
 - vs. azithromycin, 5, 12 (editorial)
 - compliance with, 1, 12 (editorial)
- Drug abuse
 - high-risk sexual behavior and, 38, 119
 - by men who have sex with men, 353
 - by sex workers, 187
 - HIV serostatus and STD incidence and, 70
 - underreporting of, hepatitis C transmission and, 220, 221 (letters)
- Dry sex, female STD incidence and, 90

E

- Enzyme-linked immunoassay, of *C. trachomatis*, false-positive results of, 418
- Epidemiologic support, for state and local STD control programs, 132
- Epidemiology, of gonorrhea, from 1981-1996, 386
- Erythromycin, for chancroid, vs. ciprofloxacin and cotrimoxazole, 293
- Ethnicity
 - diversity of sexual repertoire of, high-risk behavior and, 232
 - STD incidence in adolescents and, 125, 130 (editorial)
- Ethnographic methods, in evaluation of syphilis transmission, 154

F

- Family planning clinic, urban, chlamydia in, 317
- Female condom
 - awareness and use of, 222 (letter)
 - long-term use of, in Zambian high-risk populations, 260
- Female sex workers. *See* Sex workers
- Finland, endemic gonorrhea in, rapid decrease in, 181
- Fluoroquinolone-resistant *Neisseria gonorrhoeae*
 - in Australia, 415
 - in sparflloxacin-resistant isolate, 489
- French prisoners, heterosexual intercourse by, 217 (letter)

G

- Gardnerella vaginalis*, urethral colonization with, 448 (letter)
- Gay men. *See also* Men who have sex with men
 - high-risk behavior and condom use in, 353
 - rectal microbicides for, 296
 - young, HIV risk factors in, 100
- Gender, high-risk behavior and
 - in HIV infection, 483
 - postdiagnosis persistence of, 437
- Genital human papillomavirus infection. *See* Human papillomavirus infection
- Genital ulcer disease
 - due to granuloma inguinale, HIV infection and, 196
 - HIV infection and, in Nigerian sex workers, 237
- Genital warts, risk factors for
 - in females, 285
 - in males, 278
- Gen-Probe PACE 2 assay
 - for chlamydia and gonorrhea, in male arrestees, 501

- PCR confirmation of, DNA purification in, 265
- Gonococcal urethritis, bacterial pathogens in, 448 (letter)
- Gonorrhea. *See also* *Neisseria gonorrhoeae*
 - alcohol availability and, 544
 - azithromycin for, treatment outcome/MIC correlates for, 505
 - cefbuten for, 464
 - demographic and geographic trends in from 1981-1996, 386
 - endemic, in Finland, rapid decrease in, 181
 - Gen-Probe PACE 2 assay for, in male arrestees, 501
 - prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 - quinolone-resistant
 - in Australia, 415, 425 (editorial)
 - trends in, 415 (editorial), 425, 522
 - screening for, in middle school students, 395
 - in South African sex workers, 346
 - sparflloxacin-resistant, 489
 - urethral pathogens in, 448 (letter)
 - urine leukocyte esterase testing for, in males, 322
 - urine ligase chain reaction test for, 533
- Granuloma inguinale, HIV infection and, 196
- Group counseling, for STD/HIV prevention, 553

H

- Haemophilus ducreyi* infection, HIV infection and, in Nigerian sex workers, 237
- Haemophilus influenzae*, urethral colonization with, 448 (letter)
- Haemophilus parainfluenzae*, urethral colonization with, 448 (letter)
- Health beliefs, HIV immunization and, 76
- Health teaching, video-based, in urban STD clinic, 161
- Hepatitis C
 - transmission of, underreporting of injecting drug use and, 220, 221 (letters)
 - in women with or at risk for HIV infection, 527
- Herpes simplex virus infection, identification and control of, 58 (Paran Award Lecture)
- Herpes simplex virus type 2, HIV infection and, in Nigerian sex workers, 237
- Heterosexual intercourse, in French prison, 217 (letter)
- High-risk behavior. *See* Drug abuse; Sexual behavior, high-risk
- Homosexuals. *See also* Men who have sex with men
 - high-risk behavior and condom use in, 353
 - rectal microbicides for, 296
 - sex worker. *See* Sex workers
 - young, HIV risk factors in, 100
- Human immunodeficiency virus antibodies, oral fluid testing for, 211
- Human immunodeficiency virus infection
 - CMV seroconversion in, incidence of and risk factors for, 476, 481 (editorial)
 - female, STDs in, 443
 - genital ulcer disease and, in Nigerian sex workers, 237
 - hepatitis C and, 527
 - high-risk behavior in, gender differences in, 483
 - immunization for, health beliefs and, 76
 - infection and, granuloma inguinale and, 196
 - partner notification for, 310
 - posttest counseling for, 28
 - prevalence of, in Italian sex workers, 451
 - in prison populations, 308 (editorial)
 - prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 - rapid testing for, in Zambia, 254
 - risk assessment-based testing and counseling for, 539
 - risk factors for, in men who have sex with men, 100, 353
 - screening for
 - oral fluid testing for, 211
 - physicians' practice and opinions regarding, 169
 - social consequences of, 28
 - in South African sex workers, 346
 - in Spanish sex workers, workplace vs. income in prediction of, 194
 - tests for, failure to receive results of, 342
- Human immunodeficiency virus serostatus, STD incidence and, in female cocaine users, 70
- Human papillomavirus infection

- in Canadian Aboriginal vs. non-Aboriginal women, 55 (letter)
 - genital, detection of in college women, 243
 - risk assessment scale for, 509
 - Human rights issues, in sex work, 455
 - Human seminal plasma antigen, as semen biomarker, in condom failure, 427
 - Human T-cell lymphotropic virus type I, transmission of during sexual assault, 327 (letter)
- I**
- Immunization
 - for HIV infection, health beliefs and, 76
 - STD clinic programs for, 331
 - Intercourse. *See also* Sexual behavior
 - anal
 - female STD incidence and, 90
 - rectal microbicides for, 296
 - unprotected, in young male homosexuals, 100
 - heterosexual, in French prison, 217 (letter)
 - Interferon, for condylomata acuminata, 361
- J**
- Japan, chlamydia in pregnancy in, prevalence trends for, 516
- L**
- Leukocyte esterase test, for gonorrhea and chlamydia, in males, 322
 - Ligase chain reaction test, urine, for *N. gonorrhoeae*, 533
- M**
- Male prostitutes. *See* Sex workers
 - Menses, sex during, STD incidence and, 90
 - Men who have sex with men
 - high-risk behavior and condom use in, 353
 - HIV risk factors in, 100, 353
 - Metronidazole, vaginal gel vs. oral preparations of, for *Trichomonas vaginalis* vaginitis, 176
 - Microbicide(s), topical
 - 0.25% chlorhexidine gluconate gel as, 421
 - for female adolescents, 368
 - for gay men, 296
 - nonoxynol-9, prophylactic efficacy of, 144, 151 (editorial)
 - for trichomoniasis, vs. oral metronidazole for, 176
- N**
- Neisseria gonorrhoeae*. *See also* Gonorrhea
 - quinolone-resistant
 - in Australia, 415, 425 (editorial)
 - trends in, 415 (editorial), 425, 522
 - sparfloxacin-resistant, 489
 - urine ligase chain reaction test for, 533
 - Network approach, in evaluation of syphilis transmission, 154
 - Nigerian sex workers, genital ulcer disease and HIV in, 237
 - Noncompliance, with doxycycline therapy, 1, 12 (editorial)
 - Nongonococcal urethritis, bacterial pathogens in, 448 (letter)
 - Nonoxynol-9
 - carrageenan-based, 494
 - prophylactic efficacy of, 144, 151 (editorial)
- O**
- Ofloxacin
 - for chancroid, vs. erythromycin and cotrimoxazole, 293
 - N. gonorrhoeae* resistance to, 415, 425 (editorial)
 - Oral contraceptives users, condom use by, 139
- P**
- Pap smear, yield of, 468
 - Parran Award Lecture, 58
 - Partner notification, 218 (letter)
 - for chlamydia, in Sweden, 433
 - four-site time allocation study of, 561
 - for HIV infection, 310
 - for syphilis, 218 (letter)
 - social network approach in, 154
 - Patient education, video-based, in urban STD clinic, 161
 - Peer teen outreach, for *C. trachomatis* screening, in high-risk adolescent males, 49
 - Pelvic inflammatory disease (PID)
 - prevention of, in adolescents, 378, 395
 - social and behavioral correlates of, 378
 - Polymerase chain reaction
 - in confirmation of Gen-Probe PACE 2 results, DNA purification in, 265
 - in subtyping of *Treponema pallidum*, 408
 - in test-of-cure for azithromycin-treated chlamydia, 366
 - Post-test counseling, for HIV-infected clients, 28
 - Pregnancy
 - chlamydia in, prevalence trends for, in Japan, 516
 - HIV infection and STD screening in, 137 (editorial), 169
 - Pregnant prisoners, trichomoniasis rates and risk factors in, 303, 308 (editorial)
 - Prenatal screening, for HIV infection and STDs, 137 (editorial), 169
 - Prisoners/arrestees
 - French, heterosexual intercourse by, 217 (letter)
 - Gen-Probe PACE 2 assay for, for chlamydia and gonorrhea, 501
 - pregnant, trichomoniasis rates and risk factors in, 303, 308 (editorial)
 - STDs in, 303, 308 (editorial)
 - Prostate specific antigen, as semen biomarker, in condom failure, 427
 - Prostitutes. *See* Sex workers
- Q**
- Quinolone-resistant *Neisseria gonorrhoeae*
 - in Australia, 415, 425 (editorial)
 - in sparfloxacin-resistant isolate, 489
 - trends in, 415 (editorial), 425, 522
- R**
- Race
 - diversity of sexual repertoire and high-risk behavior and, 232
 - STD incidence in adolescents and, 125, 130 (editorial)
 - Rape, human T-cell lymphotropic virus type I transmission in, 327 (letter)
 - Rectal microbicides, for gay men, 296
 - Restriction fragment length polymorphisms, in subtyping of *Treponema pallidum*, 408
 - Risk assessment, for improved targeting of STD clinic tests and counseling for HIV infection, 539
 - Risk assessment scale, for HPV infection, 509
- S**
- Screening
 - for chlamydia, 227 (editorial)
 - DNA amplification assays for, 108
 - cost-effectiveness of, 403, 406 (letters)
 - in middle school students, 395
 - in high-risk adolescent males, 49
 - in male arrestees, Gen-Probe PACE 2 assay for, 501
 - money-saving benefits of, 53 (letter)
 - national pilot survey for, 225
 - prevalence-based program for, 201
 - in urban family planning clinic, 317
 - Gen-Probe PACE 2 assay in
 - for chlamydia and gonorrhea, in male arrestees, 501
 - DNA purification in PCR confirmation of, 265
 - for gonorrhea
 - in male arrestees, Gen-Probe PACE 2 assay for, 501
 - in middle school students, 395
 - for high-risk adolescents, 457
 - for HIV infection
 - failure to receive results of, 342
 - oral fluid testing for, 211
 - Pap smear, yield of, 468
 - prenatal, for HIV infection and STDs, 137 (editorial), 169
 - of prison populations, 308 (editorial)
 - STD reduction by, vs. by condom use, 82
 - for STDs, physicians' practice and opinions regarding, 169
 - Semen biomarkers, in condom failure, 427
 - Serologic diagnosis, of *C. trachomatis* infection, 14
 - Sex hustlers, high-risk behavior and condom use by, 353

- Sexual assault, human T-cell lymphotropic virus type I transmission in, 327 (letter)
- Sexual behavior, high-risk
 alcohol use and, 38, 119, 544
 of crack-smoking sex workers, 187
 diversity of sexual repertoire and, 232
 drug abuse and, 38, 119, 187
 female STD incidence and, 90
 in HIV infection, gender differences in, 483
 postdiagnosis persistence of, gender differences in, 437
 racial/ethnic differences in STD incidence and, 125
 underreporting of, 220, 221 (letters)
 in young male homosexuals, 100
- Sexual behavior risk scale, for HPV infection, 509
- Sexually transmitted disease clinics
 doxycycline compliance in, 1, 12 (editorial)
 failure to receive HIV test results in, 342
 immunization programs in, 331
 Pap smear screening in, yield of, 468
 risk assessment-based HIV testing and counseling in, 539
 video-based patient education in, 161
- Sexually transmitted diseases
 in adolescents, racial/ethnic differences in, 125
 anal sex and, in females, 90
 cervical atypia and, 468
 douching and, 90
 dry sex and, 90
 in female sex workers
 policy interventions for, 455 (editorial)
 reduction of by condom use vs. periodic exam program, 82
 health services for, use of by adolescents, 457
 in HIV-infected women, 443
 incidence of, HIV serostatus and, in female cocaine users, 70
 persistence of high-risk behavior after diagnosis of, gender differences in, 437
 in prison populations, 303, 308 (editorial)
 in rural South Africa, health facility-based surveillance for, 20
 screening for. *See* Screening
 sex during menses and, 90
 in Spanish sex workers, workplace vs. income in prediction of, 194
 state and local control programs for, epidemiologic support for, 132
 viral, identification and control of, 58 (Parran Award Lecture)
- Sexual repertoire, diversity of, high-risk behavior and, 232
- Sexual transmission, of hepatitis C, 527
- Sex workers
 crack-smoking, high-risk sexual behavior of, 187
 Italian, HIV seroprevalence and condom use in, 451
 male, high-risk behavior and condom use by, 353
 Nigerian, genital ulcer disease and HIV in, 237
 South African, STD prevalence in, 346
 Spanish, HIV/STD status of, workplace vs. income in prediction of, 194
 STDs in, reduction of by condom use vs. periodic exam program, 82
- Social network approach, in evaluation of syphilis transmission, 154
- Social policy, for sex work, 455
- Social services, for HIV-infected clients, 28
- Socioeconomic status, workplace vs. income and, 194
- South Africa
 STD prevalence in female sex workers, 346
 STDs in, health facility-based surveillance for, 20
- Spanish sex workers, HIV/STD status of, workplace vs. income in prediction of, 194
- Sparfloxacin, *Neisseria gonorrhoeae* resistance to, 489
- Spermicides. *See also* Topical microbicide(s)
 nonoxynol-9-containing
 carrageenan-based, 494
 prophylactic efficacy of, 144, 151 (editorial)
- Sterilization, female, planned condom use after, 335
- Stigmatized behaviors, underreporting of, 220, 221 (letters)
- Substance abuse. *See* Alcohol use/abuse; Drug abuse
- Sweden, contact tracing for chlamydia in, 433
- Syphilis
 HIV infection and, in Nigerian sex workers, 237
 molecular subtyping of *T. pallidum* for, 408
 partner notification for, 218 (letter)
 social network approach in, 154
 in South African sex workers, 346
 transmission of, social networks and ethnographic tools in evaluation of, 154
 treponemal specific tests for serodiagnosis of, 549
- T**
- Topical microbicide(s). *See also* Spermicides
 0.25% chlorhexidine gluconate gel as, 421
 for female adolescents, 368
 for gay men, 296
 nonoxynol-9, prophylactic efficacy of, 144, 151 (editorial)
 for trichomoniasis, vs. oral metronidazole for, 176
- tpr* gene, restriction fragment length polymorphism of, in subtyping of *T. pallidum*, 408
- Transcription-mediated amplification, in test-of-cure for azithromycin-treated chlamydia, 366
- Treponemal specific tests, for syphilis serodiagnosis, 549
- Treponema pallidum*, molecular subtyping of, 408
- Trichomoniasis
 in pregnant prisoners, rates of and risk factors for, 303
 in South African sex workers, 346
 vaginal gel vs. oral metronidazole for, 176
- Tubal ligation, planned condom use after, 335
- Turkey, bacterial pathogens in male urethritis patients in, 448 (letter)
- U**
- Ulcers, genital
 due to granuloma inguinale, HIV infection and, 196
 HIV infection and, in Nigerian sex workers, 237
- Urea urealyticum*, urethral colonization with, 448 (letter)
- Urethritis
 bacterial pathogens in, 448 (letter)
 gonococcal. *See* Gonorrhea
- Urinalysis, in *C. trachomatis* screening, in high-risk adolescent males, 49
- Urine leukocyte esterase testing, for gonorrhea and chlamydia, in males, 322
- Urine ligase chain reaction test, for *N. gonorrhoeae*, 533
- V**
- Vaccination
 for HIV infection, health beliefs and, 76
 STD clinics programs for, 331
- Vaginal cytology, for bacterial vaginosis, 24
- Vaginal gel metronidazole, for *Trichomonas vaginalis* vaginitis, vs. oral preparations, 176
- Vaginitis
 trichomonal
 in pregnant prisoners, rates of and risk factors for, 303
 in South African sex workers, 346
 vaginal gel vs. oral metronidazole for, 176
Trichomonas vaginalis, vaginal gel vs. oral metronidazole for, 176
- Vaginosis, bacterial
 cervical/vaginal cytology for, 24
 in South African sex workers, 346
- Video-based patient education, in urban STD clinic, 161
- Viral sexually transmitted diseases, identification and control of, 58 (Parran Award Lecture)
- W**
- Warts, genital, risk factors for
 in females, 285
 in males, 278
- Z**
- Zambia
 long-term female condom use in, 260
 rapid HIV testing in, 254